Clinical Trial Update: Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anti-PD-1 immunotherapy in combination with SBRT for patients with oligometastatic esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anti-PD-1 immunotherapy
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Esophageal Squamous Cell Carcinoma, Oligometastatic Disease | Phase 2 | Status: UNKNOWN